Related scientific articles (all)

Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.

Authors : Lalami Y, Klastersky J
Year : 2017
Journal : Crit Rev Oncol Hematol
Volume : 120
Pages : 163-179

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Authors : Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS
Year : 2017
Journal : Breast Cancer Res Treat
Volume : 163(3)
Pages : 535-544

How to emerge from the conservatism in clinical research methodology?

Authors : Kotecki N, Penel N, Awada A
Year : 2017
Journal : Curr Opin Oncol
Volume : 29(5)
Pages : 400-404

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Authors : Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Year : 2017
Journal : Front Immunol
Volume : 8
Pages : 1412

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Authors : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Year : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Car

Authors : Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, OToole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB
Year : 2017
Journal : Adv Anat Pathol
Volume : 24
Pages : 311-335

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Authors : Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, Van Poppel H, Wait S, Naredi P
Year : 2017
Journal : Eur J Cancer
Volume : 82
Pages : 193-202

Predictors of physicians' communication performance in a decision-making encounter with a simulated advanced-stage cancer patient: A longitudinal study.

Authors : Libert Y, Canivet D, Ménard C, Van Achte L, Farvacques C, Merckaert I, Liénard A, Klastersky J, Reynaert C, Slachmuylder JL, Durieux JF, Delvaux N, Razavi D
Year : 2017
Journal : Patient Educ Couns
Volume : 100(9)
Pages : 1672-9

ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Authors : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2340-2366

Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: A subset analysis of EORTC 24971 study

Authors : Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenar E, Degardin M, Pateras IS, Langendijk JA, Van Herpen C, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB
Year : 2017
Journal : Ann Oncol
Volume : 28(9)
Pages : 2213-2218

New agents for endocrine resistance in breast cancer.

Authors : Maurer C, Martel S, Zardavas D, Ignatiadis M
Year : 2017
Journal : Breast
Volume : 34
Pages : 1-11

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in I

Authors : Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, Van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, OToole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB
Year : 2017
Journal : Adv Anat Pathol
Volume : 24
Pages : 235-251

Supportive care for patients undergoing immunotherapy.

Authors : Rapoport BL, van Eeden R, Sibaud V, Epstein JB, Klastersky J, Aapro M, Moodley D
Year : 2017
Journal : Support Care Cancer
Volume : 25(10)
Pages : 3017-3030

Advances in chemical pharmacotherapy to manage advanced breast cancer.

Authors : Gombos A, Awada A
Year : 2017
Journal : Expert Opin Pharmacother
Volume : 18
Pages : 95-103

Professional Burnout in European Young Oncologists: Results of The European Society For Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.

Authors : Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH
Year : 2017
Journal : Ann Oncol
Volume : 28(7)
Pages : 1590-1596

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours.

Authors : Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M
Year : 2017
Journal : Ann Oncol
Volume : 28
Pages : iv84-iv99

Dyspnea and cardia cancer, an unusual etiology.

Authors : Speybrouck S, Claeys L, Hendlisz A, Meert AP
Year : 2017
Journal : Rev Med Brux
Volume : 38
Pages : 162-168

Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?

Authors : Kourie HR, Gharios J, Kattan J
Year : 2017
Journal : Future Oncol
Volume : 13(3)
Pages : 197-99

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Authors : Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M
Year : 2017
Journal : Nat Rev Clin Oncol
Volume : 14(11)
Pages : 669-681

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.

Authors : Najem A, Krayem M, Sales F, Hussein N, Badran B, Robert C, Awada A, Journe F, Ghanem G
Year : 2017
Journal : Eur J Cancer
Volume : 83
Pages : 154-165